Frederick S Barrett
Overview
Explore the profile of Frederick S Barrett including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
63
Citations
2361
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
DiRenzo D, Barrett F, Perin J, Darrah E, Christopher-Stine L, Griffiths R
Psychedelic Med (New Rochelle)
. 2025 Mar;
2(2):109-115.
PMID: 40051582
Background: Psilocybin is a psychedelic drug with potential therapeutic effects in patients with mood and substance use disorders. Little is known about its impact on the immune system. Methods: Multiplex...
2.
Tiwari P, Berghella A, Sayali C, Doss M, Barrett F, Yaden D
Psychedelic Med (New Rochelle)
. 2025 Mar;
1(2):74-86.
PMID: 40046726
Background: Emerging literature suggests that classic psychedelics may have efficacy in treating mood and substance use disorders in humans. This has raised questions regarding the primary therapeutic mechanism of these...
3.
Goldy S, Du B, Rohde J, Nayak S, Strickland J, Ehrenkranz R, et al.
J Psychopharmacol
. 2024 Nov;
:2698811241292951.
PMID: 39610363
Background: As classic psychedelics' therapeutic potential is studied and their popularity continues to rise, it is important to establish their relative risks and benefits. Previous surveys have tended to use...
4.
Heller N, Barrett F
Neuropsychopharmacology
. 2024 Aug;
50(1):324-325.
PMID: 39107542
No abstract available.
5.
Tani H, Yonezawa K, Kusudo K, Barrett F, Nakajima S, Uchida H
Neuropsychopharmacol Rep
. 2024 Jun;
44(3):534-539.
PMID: 38889223
Introduction: The therapeutic potential of psychedelics for various mental disorders has gained significant interest. Previous studies have highlighted that psychedelics induce psychoactive effects, including challenging aspects of experiences. These experiences...
6.
Levin A, Lancelotta R, Sepeda N, Gukasyan N, Nayak S, Wagener T, et al.
PLoS One
. 2024 Mar;
19(3):e0300501.
PMID: 38483940
We examined if the therapeutic alliance between study participants and intervention facilitators in a psilocybin-assisted therapy (PAT) trial changed over time and whether there were relationships between alliance, acute psilocybin...
7.
Barrett F, Zhou Y, Carbonaro T, Roberts J, Smith G, Griffiths R, et al.
Front Neuroergon
. 2024 Jan;
2:784576.
PMID: 38235248
Psilocybin (a serotonin 2A, or 5-HT, receptor agonist) has shown preliminary efficacy as a treatment for mood and substance use disorders. The current report utilized positron emission tomography (PET) with...
8.
ODonnell K, Anderson B, Barrett F, Bogenschutz M, Grob C, Hendricks P, et al.
Am J Psychiatry
. 2024 Jan;
181(1):74-75.
PMID: 38161295
No abstract available.
9.
Doss M, Samaha J, Barrett F, Griffiths R, de Wit H, Gallo D, et al.
Psychol Rev
. 2023 Dec;
131(2):523-562.
PMID: 38095937
Despite distinct classes of psychoactive drugs producing putatively unique states of consciousness, there is surprising overlap in terms of their effects on episodic memory and cognition more generally. Episodic memory...
10.
Nayak S, Jackson H, Sepeda N, Mathai D, So S, Yaffe A, et al.
Front Psychiatry
. 2023 Oct;
14:1199642.
PMID: 37795509
Introduction: The classic psychedelic psilocybin, found in some mushroom species, has received renewed interest in clinical research, showing potential mental health benefits in preliminary trials. Naturalistic use of psilocybin outside...